Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

220
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
220
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

898
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
898
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

646
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
646
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalizing Approaches in International Projects Engaging Individuals with Vulnerabilities: The Lessons Learned for a Person-Centered Research.

Journal of personalized medicine·2026
Same author

Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization.

International journal of antimicrobial agents·2026
Same author

Case Commentary: When susceptibility is not enough in recurrent <i>Burkholderia cenocepacia</i> infection.

Antimicrobial agents and chemotherapy·2026
Same author

Professional and patient care outcomes of e-learning in healthcare continuing education: A systematic review.

Nurse education in practice·2026
Same author

Genome sequence of a methicillin-resistant Staphylococcus epidermidis (MRSE) resistant to dalbavancin and teicoplanin isolated in Italy, 2023.

Journal of global antimicrobial resistance·2026
Same author

Adolescents' experience of bracing for idiopathic scoliosis: a systematic review and meta-analysis.

Annals of physical and rehabilitation medicine·2026
Same journal

Detection of an O1 Vibrio cholerae Strain in the Blood of a Patient with Acute Cholangitis: A Rare Case Report.

The new microbiologica·2026
Same journal

A case of Kocuria rhizophila infection and persistence in ascitic fluid of a peritoneal dialysis patient with polycystic kidney disease.

The new microbiologica·2026
Same journal

Multiple-site venous thromboembolism in acute toxoplasmosis: report of two cases.

The new microbiologica·2026
Same journal

Comparative characteristics of the microbiota of diverticula in complicated diverticulitis.

The new microbiologica·2026
Same journal

A new subtype of hepatitis E virus gene 3 has emerged in Italy and several other European countries.

The new microbiologica·2026
Same journal

Microbiological Screening of Bacterial contamination of Platelet Concentrates units: a single center observational study.

The new microbiologica·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K

Eravacycline: Data Based on Real Evidence.

Simone Giuliano1,2, Luca Martini3,2, Francesca Prataviera4,2

  • 1Department of Medicine.

The New Microbiologica
|October 22, 2025
PubMed
Summary
This summary is machine-generated.

Eravacycline shows promise for treating complex infections caused by multidrug-resistant bacteria. This real-world study found a 69.2% clinical cure rate but noted higher mortality and adverse events in some patients.

Keywords:
EravacyclineVIMbloodstream infectioncIAI

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.7K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

738

Related Experiment Videos

Last Updated: Jan 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.7K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

738

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Eravacycline is a novel synthetic fluorocycline with broad-spectrum activity against multidrug-resistant (MDR) bacteria.
  • It is engineered to overcome tetracycline resistance mechanisms, showing in vitro efficacy against pathogens like carbapenem-resistant Enterobacterales and Acinetobacter baumannii.

Purpose of the Study:

  • To evaluate the real-world effectiveness and outcomes of eravacycline in hospitalized patients with complicated infections.
  • To assess clinical cure rates, mortality, and adverse events associated with eravacycline use in a clinical setting.

Main Methods:

  • A retrospective study of 13 hospitalized patients treated with eravacycline for complicated infections between April 2023 and August 2024.
  • Data collected included patient demographics, infection characteristics, microbiological profiles, antibiotic regimens, and clinical outcomes.

Main Results:

  • A clinical cure rate of 69.2% was observed.
  • The mortality rate was 38.5%, with resistance mechanisms and inadequate source control identified in non-survivors.
  • Most patients received combination therapy, primarily with beta-lactams, and one case of suspected drug-induced hepatotoxicity was noted.

Conclusions:

  • Real-world data suggest eravacycline is effective in treating MDR infections, aligning with previous findings.
  • Limitations include a small sample size and retrospective design, necessitating further controlled studies to define its role in complex infections beyond complicated intra-abdominal infections (cIAI).